Commercial launch ramp of LIPFENDRA, Merck's newly approved oral PCSK9 inhibitor, as broad patient access begins in the U.S.
Conversion/adoption ramp for KEYTRUDA QLEX subcutaneous pembrolizumab following the April 2026 permanent J-code implementation.
OHTUVAYRE COPD launch acceleration after commercial investments and specialty-pharmacy improvements.
WINREVAIR label-expansion decision in pulmonary arterial hypertension, with a September 21, 2026 PDUFA date.
Upcoming tulisokibart Phase III ulcerative colitis maintenance readout and Phase II hidradenitis suppurativa data.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Merck & Co., Inc. and 4,900+ companies.